Ross Moat - 15 Jan 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

SEC form
4
Accepted by SEC
20 Mar 2023, 17:19:09 UTC
Prior SEC filing
06 Sep 2022
Next SEC filing
03 Apr 2023
Source filing
View source filing
Filing notes and source

Key filing fact

Ross Moat filed Form 4 for Kiniksa Pharmaceuticals, Ltd. (KNSA) on 20 Mar 2023.

Key facts

  • This page summarizes Ross Moat's Form 4 filing for Kiniksa Pharmaceuticals, Ltd. (KNSA).
  • 7 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 20 Mar 2023, 17:19.

Change

  • Previous filing in this sequence was filed on 06 Sep 2022.
  • Current net transaction value: -$1,571.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KNSA transaction

Class A Common Share

Award

Transaction value
$17,629
Shares
+1,844
Change %
+23%
Price
$9.56
Shares after
10,008
Date
15 Jan 2023
Ownership
Direct
Footnotes
F1
KNSA transaction

Class A Common Share

Options Exercise

Transaction value
Shares
+994
Change %
+9.9%
Price
Shares after
11,002
Date
16 Mar 2023
Ownership
Direct
Footnotes
F2
KNSA transaction

Class A Common Share

Tax liability

Transaction value
-$6,223
Shares
-543
Change %
-4.9%
Price
$11.46
Shares after
10,459
Date
16 Mar 2023
Ownership
Direct
KNSA transaction

Class A Common Share

Options Exercise

Transaction value
Shares
+2,137
Change %
+20%
Price
Shares after
12,596
Date
20 Mar 2023
Ownership
Direct
Footnotes
F2
KNSA transaction

Class A Common Share

Tax liability

Transaction value
-$12,977
Shares
-1,167
Change %
-9.3%
Price
$11.12
Shares after
11,429
Date
20 Mar 2023
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNSA transaction Derivative

Restricted Share Unit

Options Exercise

Transaction value
$0
Shares
-994
Change %
-33%
Price
$0.000000
Shares after
1,988
Date
16 Mar 2023
Ownership
Direct
Underlying class
Class A Common Share
Underlying amount
994
Exercise price
Footnotes
F2, F3
KNSA transaction Derivative

Restricted Share Unit

Options Exercise

Transaction value
$0
Shares
-2,137
Change %
-100%
Price
$0.000000*
Shares after
0
Date
20 Mar 2023
Ownership
Direct
Underlying class
Class A Common Share
Underlying amount
2,137
Exercise price
Footnotes
F2, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2022 to January 15, 2023. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).

Footnote F2

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

Footnote F3

The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, March 16, 2021.

Footnote F4

The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .